Regenerative Orthopedics — Complete Guide

1. What is regenerative orthopedics

Regenerative orthopedics is a medical field that uses autologous (the patient's own) biological components to trigger natural repair mechanisms in damaged musculoskeletal tissues. Unlike classical orthopedics, which relies on removing, replacing or fixing damaged structures (arthroscopy, joint replacement, arthrodesis), regenerative orthopedics restores their biology.

The method is based on three scientific discoveries of the last 30 years:

• Platelets are not just for clotting. Platelet α-granules contain over 30 growth factors (PDGF, TGF-β, VEGF, IGF-1, EGF) that drive tissue regeneration.
• Mesenchymal stem cells (MSCs). Found in adult adipose tissue and bone marrow. Capable of differentiating into chondrocytes, osteoblasts, tenocytes, myocytes.
• The regenerative microenvironment. Without the right matrix and signals, cells do not differentiate. Concentrated growth factors (CGF, PRP) create that microenvironment.

Regenerative orthopedics is used in arthrosis, tendinopathies, bursitis, disc herniations, bone necrosis, partial ligament tears, FBSS and to accelerate healing after surgery.

2. Methods of regenerative orthopedics

2.1 PRP (Platelet-Rich Plasma)

The base method of regenerative medicine. Patient blood (15–30 ml) is centrifuged once to separate erythrocytes, plasma and the buffy-coat platelet layer. Platelet concentration in the final product is 2–3× baseline. Used in early arthrosis, tendinopathies, muscle injuries. See: PRP therapy.

2.2 CGF (Concentrated Growth Factors)

An evolution of PRP. A dedicated Medifuge centrifuge with a 4-step variable-speed program is used. Result: 5–8× platelet concentration plus a dense fibrin matrix that releases growth factors slowly over 7–14 days. See: CGF therapy.

2.3 Lipogems® Ortho — micro-fragmented adipose tissue

Patient adipose tissue (~30 ml lipoaspirate) is mechanically processed in a closed Lipogems® system without enzymes or culture (compliant with EU 1394/2007). The output is a tissue product with an intact mesenchymal stem cell niche (~2.5 million MSCs per ml). Used in K-L II–III arthrosis, chronic tendinopathies, FBSS. See: Lipogems® Ortho.

2.4 BMAC (Bone Marrow Aspirate Concentrate)

A bone marrow aspirate from the posterior superior iliac spine (50–60 ml) is centrifuged into a concentrate containing hematopoietic and mesenchymal cells plus signaling molecules. Used in bone necrosis, fractures, severe K-L III arthrosis. See: stem cells.

2.5 SVF (Stromal Vascular Fraction)

An alternative to Lipogems® with enzymatic (collagenase) processing of adipose tissue. MSC concentration is higher, but EU regulatory status is ambiguous (falls under ATMP). MIBRAR® favors Lipogems® as a mechanical method authorized without a special license.

3. The MIBRAR® method — what makes it unique

MIBRAR® (Multi-modal Injection-based Biologic Articular Regeneration) is Prof. Babayan's proprietary protocol that combines the best components of all the methods above into a single regimen.

Key differences between MIBRAR® and standard PRP:

Parameter	Standard PRP	MIBRAR®
Platelet concentration	2–3×	5–8× (CGF)
Stem cells	—	Lipogems® / BMAC
Fibrin matrix	—	Yes (CGF)
Release duration	3–5 days	7–14 days
Navigation	Manual or US	Cyber Navi Hand + Sono Control Arm
Clinical effect duration	6–12 months	Lifelong

For deep structures (hip joint, epidural space, root blocks) positioning accuracy is critical. Cyber Navi Hand™ delivers 0.3 mm accuracy via optical tracking — 4× better than manual injection. See: Cyber Navi Hand™.

4. Indications and disease stages

4.1 Osteoarthritis

The main indication. Applicable to knee, hip, shoulder, ankle, interphalangeal joints. Effectiveness depends on Kellgren–Lawrence stage:

• K-L I–II: 85–92% significant improvement, full cartilage regeneration to original state.
• K-L III: 70–80% improvement, joint replacement delayed by 5–10 years.
• K-L IV: symptomatic improvement in 40–50%; joint replacement remains the method of choice.

4.2 Spinal disorders

Disc herniations L4–L5, L5–S1, C5–C6 up to 15 mm without sequestration — 75–85% avoid surgery. Protrusions — 90%. Spinal stenosis with cauda symptoms — 60–70%. Facet syndrome — 80%. FBSS — 65–75%.

4.3 Tendinopathies

Chronic tendinopathies — one of the best indications (75–92% efficacy): Achilles tendinitis, lateral epicondylitis (tennis elbow), medial epicondylitis, plantar fasciitis, rotator cuff tendinitis, biceps long-head tendinitis.

4.4 Bone necrosis and fractures

Avascular necrosis of the femoral head (ARCO I–II) — decompression + BMAC saves the joint in 70–80% of cases. Stress fractures, poorly consolidating fractures, osteoporotic vertebral fractures — BMAC accelerates consolidation up to 2-fold.

5. Contraindications and limits

Absolute: active infections (systemic or local), active malignancies, thrombocytopenia <100×10⁹/L, coagulopathies, pregnancy, lactation.

Relative: anticoagulants (require temporary withdrawal in coordination with cardiologist), uncontrolled diabetes (HbA1c >9%), heavy active smoking (>20 cigarettes/day, reduces regeneration by 30–40%), autoimmune disease in flare (requires rheumatologist coordination).

Does not work or is ineffective: full Grade III ligament tears with instability, K-L IV arthrosis with axial deformity, progressive neurological deficits (require surgery), cauda equina syndrome.

6. Evidence base

Over the past 15 years more than 1,500 randomized clinical trials and about 80 systematic reviews and meta-analyses have been published on PRP, BMAC and MSCs in orthopedics. Key sources:

• OARSI Guidelines 2019 (Osteoarthritis Cartilage) — non-surgical management of knee, hip and polyarticular OA.
• Cochrane Database Syst Rev — systematic reviews on PRP, physical therapy, HA injections for knee OA.
• NEJM, JAMA, BMJ, Lancet — landmark RCTs (Bennell 2021 RESTORE, Skou 2015 TKR vs nonsurgical, Sihvonen 2013 sham arthroscopy).
• Br J Sports Med — systematic reviews on MSCs for knee OA (Pas et al. 2017).

AAOS evidence level for most indications: 1B (good-quality RCTs) to 2A (cohort studies). For some indications (K-L II–III arthrosis, tendinopathies) — the highest level among all non-surgical methods.

7. Treatment process

The full patient journey has 6 stages:

1. Online MRI assessment (free, 48 hours). Send your scans, Prof. Babayan reviews MIBRAR® applicability.
2. Video consultation (30–45 minutes, €150, credited on arrival). Discuss plan, cost, timing.
3. Preparation (7–14 days). NSAID withdrawal 7 days, blood tests, visa, hotel, transfer. Details: preparation.
4. Onsite visit and procedure in Munich (2–3 days). Day 1 — exam, ultrasound. Day 2 — procedure (30–90 min). Day 3 — check-up and recommendations.
5. Home rehabilitation (4–12 weeks). Personalized exercise plan, coordinator support. Details: rehabilitation.
6. Follow-up (3, 6, 12 months). Video reviews, control MRI assessment, plan adjustment.

8. Expected outcomes

The dynamic of effect is typical for regenerative methods and proceeds in phases:

• 2–4 weeks: pain reduction by 30–50% via the anti-inflammatory action of CGF.
• 4–8 weeks: a possible temporary symptom plateau (the regeneration plateau).
• 8–12 weeks: a second wave of improvement — beginning of true tissue regeneration.
• 3–6 months: peak effect, visible MRI dynamics (cartilage thickness recovery, resolution of bone marrow edema).
• 6–24 months: stabilization, with continued slow improvement in many patients.

Per MIBRAR® internal data (20,000+ procedures since 2005) and independent international research: average VAS pain reduction 4–6 points out of 10, Oxford Knee/Hip Score improvement 12–20 points. 85% of patients avoid or postpone surgery for at least 5 years.

9. Frequently asked questions

10. Glossary of key terms

Autologous

Obtained from the same patient (their own blood, fat, bone marrow). The opposite of allogenic (donor) and xenogenic (from other species).

Chondrocyte

A cartilage cell. Produces type II collagen and proteoglycans — the basis of the cartilage matrix.

Mesenchymal Stem Cell (MSC)

A multipotent connective-tissue cell capable of differentiating into chondrocytes, osteoblasts, adipocytes, tenocytes.

Growth factor

A signaling protein regulating cell proliferation, differentiation and migration (PDGF, TGF-β, VEGF, IGF-1).

Kellgren–Lawrence (K-L)

Radiographic classification of arthrosis from 0 (normal) to IV (severe with deformity). Standard since 1957.

FBSS (Failed Back Surgery Syndrome)

Persistent or recurrent pain after spine surgery — laminectomy, discectomy. Affects up to 40% of operated patients.

WORMS

Whole-Organ MRI Score — standardized MRI assessment of knee osteoarthritis.

VAS

Visual Analog Scale — 0 (no pain) to 10 (maximum). Standard pain measure in clinical trials.